E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hemispatial neglect and motor deficits following right-hemisphere stroke. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042244 |
E.1.2 | Term | Stroke |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of the drug rotigotine on the syndrome of hemispatial neglect and motor deficits following right-hemisphere stroke. |
|
E.2.2 | Secondary objectives of the trial |
If rotigotine reduces hemispatial neglect, does it do so by improving memory for spatial locations, improving the ability to sustain attention or ignore distracting information, or a combination of these processes?
If motor deficits are improved by rotigotine, does the drug exert its beneficial effects by improving dexterity of the limbs? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Confirmed clinical diagnosis of right-hemisphere stroke. 2. Able to give informed consent. 3. Presence of left hemispatial neglect defined by a deficit in finding leftward targets on standard cancellation or visual search tests. (A deficit on the line bisection test alone will not be sufficient for inclusion, as a previous study shows that there is no significant relationship between performance on this test and spatial working memory capacity). 4. Presence of motor deficits: all patients will have suffered from first-ever clinically defined stroke resulting in weakness of at least wrist and finger extensors, and hand interossei (to </= 4+ on the Medical Research Council scale), at the time of recruitment. 5. Age over 18 years. 6. More than 9 days since stroke-onset (Note that on our protocol patches do not commence until a minimum of 6 days after the study begins. Thus patients will not receive drug / placebo until a minimum of 15 days post-stroke). 7. Able and willing to use patches of drug/placebo and assessments at regular intervals as defined by the protocol. 8. Able to comply with study requirements. 9. If female and of child-bearing potential, subject has a negative serum pregnancy test within two days of enrolment.
|
|
E.4 | Principal exclusion criteria |
1. Pre-existing neurological conditions that would confound cognitive and motor assessments, e.g. dementia, Parkinson’s disease, Multiple Sclerosis. 2. Presence of acute concomitant illness, e.g. infection, unstable angina, myocardial infarction or heart, respiratory, renal or liver failure which, based on clinical judgment, would be considered to confound interpretation of results. 3. Systolic blood pressure less than 120 mmHg and / or diastolic less than 70 mmHg. 4. Exposure to any other investigational drug within 30 days of enrollment in the study. 5. History (obtained from patient and medical records) of clinically significant drug or alcohol abuse within 6 months prior to enrolment into the study. 6. Pregnancy (because the effects of rotigotine on the foetus and mother in pregnancy are not known). If female and of child-bearing potential, a serum pregnancy test will be performed within two days of enrolment. 7. Mothers who are breast feeding (because the effects of rotigotine on the newborn have not been established)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Completion of study protocol which lasts 5 weeks and 3 days for every participant. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Randomization test design (originally developed by Fisher) |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is last assessment of last subject undergoing trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |